Loading…
Effect of Centratherum anthelminticum seeds on Glycated hemoglobin, Cardiovascular disease risks and dyslipidemia in Type-2 diabetic patients in Karachi: A non-blind randomized controlled trial
To explore the effect of seeds powder { 500 mg} capsule in diabetes Type-2 (T2DM) patients in Karachi. A randomized selection of 40 T2DM patients from Sindh Government Hospital New Karachi with their consents was done for a non-blinded controlled trial from October to December 2019 and divided into...
Saved in:
| Published in: | Pakistan journal of medical sciences 2025-01, Vol.41 (1), p.257-262 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | 262 |
| container_issue | 1 |
| container_start_page | 257 |
| container_title | Pakistan journal of medical sciences |
| container_volume | 41 |
| creator | Mudassir, Hina Akram Arshad, Syed Muhammed Talha Naheed, Munazzah Anwer, Sadia |
| description | To explore the effect of
seeds powder {
500 mg} capsule in diabetes Type-2 (T2DM) patients in Karachi.
A randomized selection of 40 T2DM patients from Sindh Government Hospital New Karachi with their consents was done for a non-blinded controlled trial from October to December 2019 and divided into P
(Positive Control, metformin 500 mg) & T
(Test,
+ was also included, using the same dosage of CapCASP on twenty healthy volunteers. The data were analyzed using an online graph pad student's t-test and a one-way ANOVA (SPSS version 24) metformin 500mg each). Both groups had (n = 20). C
(healthy control), was also included with twenty healthy volunteers with same dose of
. The biochemical tests (lipid profile, HbA1c, fasting blood glucose) of both groups were done in biochemistry lab Federal Urdu University of Arts, Science & Technology and results were analyzed by one-way ANOVA (SPSS version 24) and online graph pad student´s t-test.
CASP showed potent (
) anti-diabetic activity (72.81%) than standard acarbose (standard drug). Most of
parameters in T
showed significant improvements. Body weight ( |
| doi_str_mv | 10.12669/pjms.41.1.8496 |
| format | article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_crossref_primary_10_12669_pjms_41_1_8496</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A824773822</galeid><sourcerecordid>A824773822</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-869acee4e212f52409db196bd491dd175a97d9102fefd3941a59649ff5e9a60a3</originalsourceid><addsrcrecordid>eNptkk1v1DAQhiMEoqVw5oYsISEOZGs7zoe5oNWqFEQlLkXqzXLi8caLYwc7qbT8O_4ZzraUFiEfPPY88854PFn2kuAVoVXFT8fdEFeMrMiqYbx6lB2TqiF5Tcqrxweb5piyq6PsWYw7jFnFSvo0Oyp4U9UNro6zX2daQzchr9EG3BTk1EOYByRdMuxg3GS6dIwAKiLv0Lndd3IChXoY_Nb61rh3aCODMv5axm62MiBlIsgIKJj4PSYlhdQ-WjMaBYORyDh0uR8hpwmULaQEaJSTSdnj4vsig-x68x6tkfMub61JAiGp-MH8TIk7n8r01iZzCkba59kTLW2EF7f7Sfbt49nl5lN-8fX882Z9kXcMsylvKi47AAaUUF1ShrlqCa9axThRitSl5LXiBFMNWhWcEVnyinGtS-CywrI4yT7c6I5zO4DqDt2yYgxmkGEvvDTioceZXmz9tSBJvKQ1SQpvbxWC_zFDnMRgYgfWSgd-jqIgFcY1aYoFff0PuvNzcOl9iUqFFbTk9V9qKy0I47RPibtFVKwbyuq6aChN1Oo_VFrLd6Rugjbp_kHAm3sBPUg79dHbeTLexYfg6Q3YBR9jAH3XDYLFYT7FMp-CEUHEMp8p4tX9Jt7xfway-A2DueTC</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3159632597</pqid></control><display><type>article</type><title>Effect of Centratherum anthelminticum seeds on Glycated hemoglobin, Cardiovascular disease risks and dyslipidemia in Type-2 diabetic patients in Karachi: A non-blind randomized controlled trial</title><source>Nexis UK</source><source>Open Access: PubMed Central</source><creator>Mudassir, Hina Akram ; Arshad, Syed Muhammed Talha ; Naheed, Munazzah ; Anwer, Sadia</creator><creatorcontrib>Mudassir, Hina Akram ; Arshad, Syed Muhammed Talha ; Naheed, Munazzah ; Anwer, Sadia</creatorcontrib><description><![CDATA[To explore the effect of
seeds powder {
500 mg} capsule in diabetes Type-2 (T2DM) patients in Karachi.
A randomized selection of 40 T2DM patients from Sindh Government Hospital New Karachi with their consents was done for a non-blinded controlled trial from October to December 2019 and divided into P
(Positive Control, metformin 500 mg) & T
(Test,
+ was also included, using the same dosage of CapCASP on twenty healthy volunteers. The data were analyzed using an online graph pad student's t-test and a one-way ANOVA (SPSS version 24) metformin 500mg each). Both groups had (n = 20). C
(healthy control), was also included with twenty healthy volunteers with same dose of
. The biochemical tests (lipid profile, HbA1c, fasting blood glucose) of both groups were done in biochemistry lab Federal Urdu University of Arts, Science & Technology and results were analyzed by one-way ANOVA (SPSS version 24) and online graph pad student´s t-test.
CASP showed potent (
) anti-diabetic activity (72.81%) than standard acarbose (standard drug). Most of
parameters in T
showed significant improvements. Body weight (
<0.01) & (
<0.05), HbA1c & fasting blood glucose (
<0.0001), coronary risk index (CRI), atherogenic index (A Indx) (
<0.05,
<0.0001) & atherogenic dyslipidemia ratio (A-DLR) (
<0.0001 &
<0.01) were reduced after six and twelve weeks. Reduction in serum cholesterol and triglycerides (
< 0.05 &
< 0.01) after six as well as (
< 0.01) after twelve weeks. Very low density lipoprotein reduced after both (
< 0.05) six and (
< 0.0001) twelve weeks. High density lipoprotein increased (
< 0.01) & low density lipoprotein decreased (
< 0.05) after twelve weeks.
When given standard care to T2D patients, the CASP intervention demonstrated both anti-diabetic and anti-lipidemic effects.]]></description><identifier>ISSN: 1682-024X</identifier><identifier>EISSN: 1681-715X</identifier><identifier>DOI: 10.12669/pjms.41.1.8496</identifier><identifier>PMID: 39867806</identifier><language>eng</language><publisher>Pakistan: Knowledge Bylanes</publisher><subject>Antidiabetics ; Biomarkers ; Blood sugar ; Cardiovascular disease ; Cardiovascular diseases ; Clinical trials ; Diabetes ; Diabetics ; Glucose ; Glycosylated hemoglobin ; Hemoglobin ; High density lipoprotein ; Hospitals ; Hyperglycemia ; Insulin resistance ; Lipids ; Low density lipoprotein ; Metabolic disorders ; Original ; Ratios ; Research methodology ; Risk factors ; Seeds ; Triglycerides ; Type 2 diabetes</subject><ispartof>Pakistan journal of medical sciences, 2025-01, Vol.41 (1), p.257-262</ispartof><rights>Copyright: © Pakistan Journal of Medical Sciences.</rights><rights>COPYRIGHT 2025 Knowledge Bylanes</rights><rights>(c)2025 Pakistan Journal of Medical Sciences</rights><rights>Copyright: © Pakistan Journal of Medical Sciences 2025</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11755271/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11755271/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39867806$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mudassir, Hina Akram</creatorcontrib><creatorcontrib>Arshad, Syed Muhammed Talha</creatorcontrib><creatorcontrib>Naheed, Munazzah</creatorcontrib><creatorcontrib>Anwer, Sadia</creatorcontrib><title>Effect of Centratherum anthelminticum seeds on Glycated hemoglobin, Cardiovascular disease risks and dyslipidemia in Type-2 diabetic patients in Karachi: A non-blind randomized controlled trial</title><title>Pakistan journal of medical sciences</title><addtitle>Pak J Med Sci</addtitle><description><![CDATA[To explore the effect of
seeds powder {
500 mg} capsule in diabetes Type-2 (T2DM) patients in Karachi.
A randomized selection of 40 T2DM patients from Sindh Government Hospital New Karachi with their consents was done for a non-blinded controlled trial from October to December 2019 and divided into P
(Positive Control, metformin 500 mg) & T
(Test,
+ was also included, using the same dosage of CapCASP on twenty healthy volunteers. The data were analyzed using an online graph pad student's t-test and a one-way ANOVA (SPSS version 24) metformin 500mg each). Both groups had (n = 20). C
(healthy control), was also included with twenty healthy volunteers with same dose of
. The biochemical tests (lipid profile, HbA1c, fasting blood glucose) of both groups were done in biochemistry lab Federal Urdu University of Arts, Science & Technology and results were analyzed by one-way ANOVA (SPSS version 24) and online graph pad student´s t-test.
CASP showed potent (
) anti-diabetic activity (72.81%) than standard acarbose (standard drug). Most of
parameters in T
showed significant improvements. Body weight (
<0.01) & (
<0.05), HbA1c & fasting blood glucose (
<0.0001), coronary risk index (CRI), atherogenic index (A Indx) (
<0.05,
<0.0001) & atherogenic dyslipidemia ratio (A-DLR) (
<0.0001 &
<0.01) were reduced after six and twelve weeks. Reduction in serum cholesterol and triglycerides (
< 0.05 &
< 0.01) after six as well as (
< 0.01) after twelve weeks. Very low density lipoprotein reduced after both (
< 0.05) six and (
< 0.0001) twelve weeks. High density lipoprotein increased (
< 0.01) & low density lipoprotein decreased (
< 0.05) after twelve weeks.
When given standard care to T2D patients, the CASP intervention demonstrated both anti-diabetic and anti-lipidemic effects.]]></description><subject>Antidiabetics</subject><subject>Biomarkers</subject><subject>Blood sugar</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Clinical trials</subject><subject>Diabetes</subject><subject>Diabetics</subject><subject>Glucose</subject><subject>Glycosylated hemoglobin</subject><subject>Hemoglobin</subject><subject>High density lipoprotein</subject><subject>Hospitals</subject><subject>Hyperglycemia</subject><subject>Insulin resistance</subject><subject>Lipids</subject><subject>Low density lipoprotein</subject><subject>Metabolic disorders</subject><subject>Original</subject><subject>Ratios</subject><subject>Research methodology</subject><subject>Risk factors</subject><subject>Seeds</subject><subject>Triglycerides</subject><subject>Type 2 diabetes</subject><issn>1682-024X</issn><issn>1681-715X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><recordid>eNptkk1v1DAQhiMEoqVw5oYsISEOZGs7zoe5oNWqFEQlLkXqzXLi8caLYwc7qbT8O_4ZzraUFiEfPPY88854PFn2kuAVoVXFT8fdEFeMrMiqYbx6lB2TqiF5Tcqrxweb5piyq6PsWYw7jFnFSvo0Oyp4U9UNro6zX2daQzchr9EG3BTk1EOYByRdMuxg3GS6dIwAKiLv0Lndd3IChXoY_Nb61rh3aCODMv5axm62MiBlIsgIKJj4PSYlhdQ-WjMaBYORyDh0uR8hpwmULaQEaJSTSdnj4vsig-x68x6tkfMub61JAiGp-MH8TIk7n8r01iZzCkba59kTLW2EF7f7Sfbt49nl5lN-8fX882Z9kXcMsylvKi47AAaUUF1ShrlqCa9axThRitSl5LXiBFMNWhWcEVnyinGtS-CywrI4yT7c6I5zO4DqDt2yYgxmkGEvvDTioceZXmz9tSBJvKQ1SQpvbxWC_zFDnMRgYgfWSgd-jqIgFcY1aYoFff0PuvNzcOl9iUqFFbTk9V9qKy0I47RPibtFVKwbyuq6aChN1Oo_VFrLd6Rugjbp_kHAm3sBPUg79dHbeTLexYfg6Q3YBR9jAH3XDYLFYT7FMp-CEUHEMp8p4tX9Jt7xfway-A2DueTC</recordid><startdate>20250131</startdate><enddate>20250131</enddate><creator>Mudassir, Hina Akram</creator><creator>Arshad, Syed Muhammed Talha</creator><creator>Naheed, Munazzah</creator><creator>Anwer, Sadia</creator><general>Knowledge Bylanes</general><general>AsiaNet Pakistan (Pvt) Ltd</general><general>Professional Medical Publications</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20250131</creationdate><title>Effect of Centratherum anthelminticum seeds on Glycated hemoglobin, Cardiovascular disease risks and dyslipidemia in Type-2 diabetic patients in Karachi: A non-blind randomized controlled trial</title><author>Mudassir, Hina Akram ; Arshad, Syed Muhammed Talha ; Naheed, Munazzah ; Anwer, Sadia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-869acee4e212f52409db196bd491dd175a97d9102fefd3941a59649ff5e9a60a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Antidiabetics</topic><topic>Biomarkers</topic><topic>Blood sugar</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Clinical trials</topic><topic>Diabetes</topic><topic>Diabetics</topic><topic>Glucose</topic><topic>Glycosylated hemoglobin</topic><topic>Hemoglobin</topic><topic>High density lipoprotein</topic><topic>Hospitals</topic><topic>Hyperglycemia</topic><topic>Insulin resistance</topic><topic>Lipids</topic><topic>Low density lipoprotein</topic><topic>Metabolic disorders</topic><topic>Original</topic><topic>Ratios</topic><topic>Research methodology</topic><topic>Risk factors</topic><topic>Seeds</topic><topic>Triglycerides</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mudassir, Hina Akram</creatorcontrib><creatorcontrib>Arshad, Syed Muhammed Talha</creatorcontrib><creatorcontrib>Naheed, Munazzah</creatorcontrib><creatorcontrib>Anwer, Sadia</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database (ProQuest)</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pakistan journal of medical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mudassir, Hina Akram</au><au>Arshad, Syed Muhammed Talha</au><au>Naheed, Munazzah</au><au>Anwer, Sadia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Centratherum anthelminticum seeds on Glycated hemoglobin, Cardiovascular disease risks and dyslipidemia in Type-2 diabetic patients in Karachi: A non-blind randomized controlled trial</atitle><jtitle>Pakistan journal of medical sciences</jtitle><addtitle>Pak J Med Sci</addtitle><date>2025-01-31</date><risdate>2025</risdate><volume>41</volume><issue>1</issue><spage>257</spage><epage>262</epage><pages>257-262</pages><issn>1682-024X</issn><eissn>1681-715X</eissn><abstract><![CDATA[To explore the effect of
seeds powder {
500 mg} capsule in diabetes Type-2 (T2DM) patients in Karachi.
A randomized selection of 40 T2DM patients from Sindh Government Hospital New Karachi with their consents was done for a non-blinded controlled trial from October to December 2019 and divided into P
(Positive Control, metformin 500 mg) & T
(Test,
+ was also included, using the same dosage of CapCASP on twenty healthy volunteers. The data were analyzed using an online graph pad student's t-test and a one-way ANOVA (SPSS version 24) metformin 500mg each). Both groups had (n = 20). C
(healthy control), was also included with twenty healthy volunteers with same dose of
. The biochemical tests (lipid profile, HbA1c, fasting blood glucose) of both groups were done in biochemistry lab Federal Urdu University of Arts, Science & Technology and results were analyzed by one-way ANOVA (SPSS version 24) and online graph pad student´s t-test.
CASP showed potent (
) anti-diabetic activity (72.81%) than standard acarbose (standard drug). Most of
parameters in T
showed significant improvements. Body weight (
<0.01) & (
<0.05), HbA1c & fasting blood glucose (
<0.0001), coronary risk index (CRI), atherogenic index (A Indx) (
<0.05,
<0.0001) & atherogenic dyslipidemia ratio (A-DLR) (
<0.0001 &
<0.01) were reduced after six and twelve weeks. Reduction in serum cholesterol and triglycerides (
< 0.05 &
< 0.01) after six as well as (
< 0.01) after twelve weeks. Very low density lipoprotein reduced after both (
< 0.05) six and (
< 0.0001) twelve weeks. High density lipoprotein increased (
< 0.01) & low density lipoprotein decreased (
< 0.05) after twelve weeks.
When given standard care to T2D patients, the CASP intervention demonstrated both anti-diabetic and anti-lipidemic effects.]]></abstract><cop>Pakistan</cop><pub>Knowledge Bylanes</pub><pmid>39867806</pmid><doi>10.12669/pjms.41.1.8496</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1682-024X |
| ispartof | Pakistan journal of medical sciences, 2025-01, Vol.41 (1), p.257-262 |
| issn | 1682-024X 1681-715X |
| language | eng |
| recordid | cdi_crossref_primary_10_12669_pjms_41_1_8496 |
| source | Nexis UK; Open Access: PubMed Central |
| subjects | Antidiabetics Biomarkers Blood sugar Cardiovascular disease Cardiovascular diseases Clinical trials Diabetes Diabetics Glucose Glycosylated hemoglobin Hemoglobin High density lipoprotein Hospitals Hyperglycemia Insulin resistance Lipids Low density lipoprotein Metabolic disorders Original Ratios Research methodology Risk factors Seeds Triglycerides Type 2 diabetes |
| title | Effect of Centratherum anthelminticum seeds on Glycated hemoglobin, Cardiovascular disease risks and dyslipidemia in Type-2 diabetic patients in Karachi: A non-blind randomized controlled trial |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T08%3A11%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Centratherum%20anthelminticum%20seeds%20on%20Glycated%20hemoglobin,%20Cardiovascular%20disease%20risks%20and%20dyslipidemia%20in%20Type-2%20diabetic%20patients%20in%20Karachi:%20A%20non-blind%20randomized%20controlled%20trial&rft.jtitle=Pakistan%20journal%20of%20medical%20sciences&rft.au=Mudassir,%20Hina%20Akram&rft.date=2025-01-31&rft.volume=41&rft.issue=1&rft.spage=257&rft.epage=262&rft.pages=257-262&rft.issn=1682-024X&rft.eissn=1681-715X&rft_id=info:doi/10.12669/pjms.41.1.8496&rft_dat=%3Cgale_pubme%3EA824773822%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c404t-869acee4e212f52409db196bd491dd175a97d9102fefd3941a59649ff5e9a60a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3159632597&rft_id=info:pmid/39867806&rft_galeid=A824773822&rfr_iscdi=true |